American Century Companies Inc. Has $38.92 Million Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

American Century Companies Inc. cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 18.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,923,465 shares of the biopharmaceutical company’s stock after selling 877,434 shares during the quarter. American Century Companies Inc.’s holdings in Amicus Therapeutics were worth $38,921,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Comerica Bank increased its stake in shares of Amicus Therapeutics by 0.8% in the fourth quarter. Comerica Bank now owns 103,418 shares of the biopharmaceutical company’s stock worth $1,468,000 after acquiring an additional 774 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Amicus Therapeutics by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 54,943 shares of the biopharmaceutical company’s stock worth $780,000 after purchasing an additional 1,258 shares in the last quarter. American International Group Inc. boosted its holdings in Amicus Therapeutics by 0.9% in the fourth quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock worth $2,004,000 after purchasing an additional 1,298 shares in the last quarter. Arizona State Retirement System boosted its holdings in Amicus Therapeutics by 2.6% in the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock worth $615,000 after purchasing an additional 1,577 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in Amicus Therapeutics by 1.1% in the second quarter. Principal Financial Group Inc. now owns 240,813 shares of the biopharmaceutical company’s stock worth $2,389,000 after purchasing an additional 2,737 shares in the last quarter.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $10,382,718.34. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $8,866,540. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. The disclosure for this sale can be found here. Insiders have sold a total of 21,100 shares of company stock valued at $226,375 over the last three months. 2.20% of the stock is owned by corporate insiders.

Amicus Therapeutics Stock Up 1.3 %

FOLD stock opened at $11.20 on Wednesday. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.57. The company has a market cap of $3.32 billion, a PE ratio of -22.82 and a beta of 0.69. The business’s 50-day simple moving average is $10.98 and its 200 day simple moving average is $10.76. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. During the same period last year, the business earned ($0.15) earnings per share. The firm’s revenue for the quarter was up 34.0% compared to the same quarter last year. On average, research analysts anticipate that Amicus Therapeutics, Inc. will post -0.08 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on FOLD. JPMorgan Chase & Co. decreased their price objective on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Wells Fargo & Company began coverage on shares of Amicus Therapeutics in a report on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price objective for the company. Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.25.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.